AstraZeneca: Crestor lowers 'bad' cholesterol among various ethnicities

By Elaine Rigoli

Tampa, Fla., June 22 - AstraZeneca said data from an analysis of three prospective studies demonstrate that Crestor (rosuvastatin calcium) effectively reduced cholesterol levels in several distinct ethnic populations that have generally been underrepresented in clinical trials - African American, Hispanic American and South Asian American.

The three studies are intended to investigate the impact of Crestor on cardiovascular risk reduction and patient outcomes, the company said in a news release.

These ethnic groups represent a significant - and growing - sector of the U.S. population and have specific health-related concerns based on genetics, demographic structure and other cultural factors, officials noted.

AstraZeneca is an international health care business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and health care services.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.